Binimetinib is an investigational, oral small-molecule targeting the mitogen-activated protein kinase (MAPK) pathway. Mitogen-activated protein kinase enzyme (MEK) is a key protein kinase in the MAPK pathway, which regulates several key cellular activities, including proliferation, differentiation, migration, survival, and angiogenesis. Inappropriate activation of this pathway has been shown to occur in many cancers.  This report addresses the use of binimetinib in NRAS-mutated melanoma; it is also in development for BRAF-mutated melanoma.

If you have a Hayes login, click here to view the full report on the Knowledge Center.